Clinical trials / NCT06093022
Recruiting

Surgical or Medical Treatment of Breast Cancer Metastasis: A Multicentre Observational Study

The liver represents the third most common site of breast cancer (BC) metastases behind the lymphatics and bone. The primary treatment for BCLM remains chemo-therapy and, more recently, targeted immunotherapy. The role of liver resection in BCLM remains controversial. The primary aim of the study is to compare the efficacy of liver resection vs. medical therapy alone in Breast Cancer Liver Metastasis (BCLM) patients.

ClinicalTrials.gov IDNCT06093022
PhaseNot Applicable
Enrollment720
SponsorFondazione Policlinico Universitario Agostino Gemelli IRCCS
Age18 Years
SexALL
I'm interested View official listing

Conditions studied

Breast Cancer, Liver Metastases

About this study

The liver represents the third most common site of breast cancer (BC) metastases behind the lymphatics and bone. The primary treatment for BCLM remains chemo-therapy and, more recently, targeted immunotherapy. The role of liver resection in BCLM remains controversial. The primary aim of the study is to compare the efficacy of liver resection vs. medical therapy alone in Breast Cancer Liver Metastasis (BCLM) patients.

Primary outcomes

Eligibility information

Inclusion Criteria: * \> 18 years old * BCLM * BCLM and extra-hepatic disease * Any treatment * Ability to understand and sign the informed consent Exclusion Criteria: * Inability to provide the informed consent * Patient who underwent Best Supportive Care or Palliation

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.